Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against SELLAS Life Sciences Group, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is SELLAS Life Sciences Group, Inc. (SLS) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SELLAS Life Sciences Group, Inc. (“SELLAS” or “the Company”) (NASDAQ: SLS). Investors who purchased SELLAS securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether SELLAS has violated federal securities laws.
What Potential Securities Violations Is BG&G Investigating?
On August 28, 2026, a news site reported that the Company’s phase 3 clinical trial for Galinpepimut-S (GPS) had reached its 80th patient death, a pre-specified event that was to trigger the release of results for the clinical trial. However, as of the time of that report, Sellas had yet to release the trial results. Following this news, Sellas’s stock price fell $2.00 per share, or 13.15%, to close at $13.21 per share on August 28, 2026.
What Should SELLAS Life Sciences Group, Inc. (SLS) Investors Do?
If you are aware of any facts relating to this investigation or purchased SELLAS securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
How Did SELLAS Life Sciences Group, Inc. (SLS) Stock React?
How Does BG&G Help Investors in Securities Fraud Investigations?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”